Leerink Partnrs Issues Pessimistic Outlook for MNMD Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Equities research analysts at Leerink Partnrs cut their Q4 2025 earnings estimates for Mind Medicine (MindMed) in a note issued to investors on Sunday, November 9th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of ($0.54) for the quarter, down from their previous forecast of ($0.53). The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Mind Medicine (MindMed)’s FY2026 earnings at ($1.95) EPS, FY2027 earnings at ($2.00) EPS and FY2028 earnings at ($2.05) EPS.

Several other equities research analysts have also issued reports on the company. Canaccord Genuity Group raised their price objective on Mind Medicine (MindMed) from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Lifesci Capital upgraded Mind Medicine (MindMed) to a “strong-buy” rating in a report on Tuesday, October 14th. Oppenheimer began coverage on shares of Mind Medicine (MindMed) in a research note on Monday, August 4th. They set an “outperform” rating and a $25.00 price objective for the company. Royal Bank Of Canada cut their price objective on shares of Mind Medicine (MindMed) from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Friday, November 7th. Finally, Needham & Company LLC set a $28.00 target price on shares of Mind Medicine (MindMed) and gave the stock a “buy” rating in a report on Monday, October 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $26.50.

Mind Medicine (MindMed) Trading Up 6.2%

MNMD opened at $12.48 on Wednesday. The stock has a 50-day moving average of $11.40 and a 200 day moving average of $9.21. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31. Mind Medicine has a 12 month low of $4.70 and a 12 month high of $14.43. The firm has a market cap of $949.60 million, a P/E ratio of -6.12 and a beta of 2.57.

Mind Medicine (MindMed) (NASDAQ:MNMD) last posted its earnings results on Thursday, November 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26).

Hedge Funds Weigh In On Mind Medicine (MindMed)

A number of institutional investors have recently modified their holdings of the stock. Commodore Capital LP raised its stake in shares of Mind Medicine (MindMed) by 10.5% during the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after acquiring an additional 475,000 shares in the last quarter. Marshall Wace LLP raised its position in Mind Medicine (MindMed) by 31.9% during the 2nd quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock valued at $22,204,000 after purchasing an additional 828,067 shares in the last quarter. Vanguard Group Inc. raised its position in Mind Medicine (MindMed) by 11.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after purchasing an additional 198,878 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Mind Medicine (MindMed) by 4.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock worth $11,252,000 after buying an additional 66,663 shares during the period. Finally, AWM Investment Company Inc. grew its position in shares of Mind Medicine (MindMed) by 0.6% during the 2nd quarter. AWM Investment Company Inc. now owns 1,215,662 shares of the company’s stock worth $7,890,000 after buying an additional 7,500 shares in the last quarter. 27.91% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Mark Sullivan sold 11,278 shares of the company’s stock in a transaction dated Thursday, September 25th. The shares were sold at an average price of $9.77, for a total value of $110,186.06. Following the transaction, the insider directly owned 293,852 shares in the company, valued at approximately $2,870,934.04. This represents a 3.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Robert Barrow sold 25,797 shares of Mind Medicine (MindMed) stock in a transaction dated Thursday, September 25th. The shares were sold at an average price of $9.77, for a total transaction of $252,036.69. Following the sale, the chief executive officer owned 804,268 shares of the company’s stock, valued at $7,857,698.36. The trade was a 3.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 44,779 shares of company stock worth $437,491 over the last quarter. Company insiders own 2.26% of the company’s stock.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.